43 results about "Antiparkinsonian drugs" patented technology

The invention discloses an improved preparing method of anti-parkinson medicine detonate sand java blue important intermediate 2, 3- di-hydrogen- 1H-indenes-1-amine, which is characterized by the following: reacting 2, 3- di-hydrogen- 1H-indenes-1-ketoximes and alumino-nickel in queous alkali getting the product. This invention also discloses a 'one pot boiling' preparing method of 2, 3- di-hydrogen- 1H-indenes-1-amine with 2, 3- di-hydrogen- 1H-indenes-1- ketone. This invention also discloses a 'two steps one pot boiling' preparing method and 'three steps one pot boiling' preparing method of detonate sand java blue with 2, 3- di-hydrogen- 1H-indenes-1-ketoxime and 2, 3- di-hydrogen- 1H-indenes-1- ketone. This invention possesses simple operation, low cost and high productive efficiency, which is fit for industrial production.

The invention discloses a long-acting sustained-release preparation for resisting Parkinson's disease and a preparation method thereof. The long-acting sustained-release preparation refers to microspheres, each microsphere comprises rasagiline or pharmaceutically acceptable salt thereof and biodegradable high-biocompatibility molecular polymer, and the microspheres includes the microspheres with the average particle size of 0.5-5 micrometers and the microspheres with the average particle size of 20-150 micrometers. The two kinds of microspheres different in particle size are properly matched and used in the pharmaceutical composition, the fluctuation of the concentration of rasagiline in plasma can be significantly reduced, and there is no obvious delayed release period. At the same time, the long-acting sustained-release preparation has no drug releasing phenomenon under the condition of high drug loading.

The invention discloses atractylenolide extract having antiparkinsonian effect, a preparation method and application thereof. Weight percentages of atractylenolide I, atractylenolide II and atractylenolide III in the atractylenolide extract are larger than 5%, 10% and 20% respectively, and purity of total lactone is larger than 35%. The application refers to that the atractylenolide extract is used to prepare antiparkinsonian drug. The preparation method includes that oxidant is added into white atractylode rhizome powder, and atractylone in white atractylode rhizome volatile oil is oxidized into atractylenolide compounds, so that content of atractylenolide is increased; zinc particles are added into an extraction solution to protect generated compounds such as atractylenolide from being further oxidized and degraded. The preparation method is simple, convenient and practical, easy to operate and more suitable for industrial production, and has remarkable progressiveness and practical value.

The invention discloses application of a compound tekaning (Chinese character) with a structure in a formula (I) in the specification in preparation of a mitochondrial injury protective agent. In addition, the invention also discloses the mitochondrial injury protective agent of which the effective component is the compound tekaning with the structure in the formula (I). The application fully proves that the compound tekaning, and drugs, drinks or health products containing effective components of the compound tekaning can be used for effectively promoting expression of mitochondrial autophagy key signal molecules, and enhancing mitochondrial autophagy to inhibit the mitochondrial injury, so as to effectively clear mitochondrial dysfunction existing in cortical neuron, especially, dopaminergic neurons of the brain of which the mitochondrial mass is relatively low. Thus, the dopaminergic neuron is protected to play the roles of relieving parkinson's disease and the like and treating a nerve disease.

The invention discloses an application of imatinib mesylate in preparation of drugs for resisting Parkinson's disease (PD). The application of imatinib mesylate (STI571) in preparation of drugs for treating neurodegenerative diseases belongs to the protective range of the invention, and the neurodegenerative diseases can be PD. An experiment proves that by continuous administration of the STI571, the dyskinesia induced by MPTP can be obviously improved, and the cognitive dysfunction of mice can be improved. The STI571 can obviously improve the dopaminergic neuron loss induced by the MPTP, can inhibit the rat CA1 and DG (diacylglycerol) region nerve cell apoptosis reaction induced by rotenone, can obviously inhibit the primary substantia nigra neuron apoptosis and Lewy protein expression induced by rotenone, and can inhibit the phosphorylation activation of PKC (Protein Kinase C) and Akt. The STI571 used as a specific inhibitor of c-Ab1 can resist the formation of PD, can improve the behavioral abnormity and cognitive dysfunction of PD, can be used as a new candidate drug for resisting neurodegenerative diseases such as PD and the like, and has favorable application prospects; and the clinical indications of the STI571 are greatly expanded.

The invention discloses an alkaloid compound with a 1,2,3-triazole structure segment and application of the compound.The compound has the general structural formula as shown in the description.The alkaloid compound with the 1,2,3-triazole structure segment is novel in structure, synthetic route operation is easy and convenient, the yield is high, and the safety is good.It is proved through experiments that the compound has certain inhibitory activity on Keap1-Nrf2 protein and protein interaction, and it is promoted through research results that the compound has potential application in the drug research field of tumor resistance, inflammation resistance, Parkinson's disease resistance and Alzheimer's disease resistance.

A synthesis method of metixene hydrochloride relates to a synthesis process of an antiparkinsonian drug. The synthesis method comprises the following steps: taking thiosalicylic acid as a raw material to obtain 2-thiophenyl benzoic acid by coupling with iodobenzene; then dehydrating and cyclizing to obtain 9-thioxanthone; reducing a carbonyl to obtain thioxanthene; and finally allowing the thioxanthene to react with 3-chloromethyl-1-pipecoline to obtain the target product (5) metixene hydrochloride shown as a formula (5) below. The synthesis method has the advantages of available raw materials, low cost, short preparation course, simple operation and easy industrialization, and helps produce the metixene hydrochloride which is the antiparkinsonian drug.

The invention discloses a synthesis method for dopa-containing oligopeptide and application of the dopa-containing oligopeptide in antiparkinsonian prodrugs. According to the synthesis route, in the synthesis process, a prepared dopa-containing dipeptide intermediate protected by actonide has good stability and can be stably stored for a long time, and the dopa-containing dipeptide can be converted only in one step, which overcomes the defects that the dopa-containing dipeptide structure is not stable and cannot be stored for a long time. The method has the advantages that the universality isgood, the defect that a reflux reaction is needed in the prior art is overcome, the reaction condition is mild, side reactions are fewer, the cost of raw materials is lower, and the product has higherpurity and is easy to separate; the prepared dopa-containing dipeptide has good stability in liver homogenate and strong degradation resistance, is expected to be developed into a high-bioavailability and long-acting Parkinson's disease treatment drug, and is expected to significantly reduce the side effects of L-DOPA in treating the Parkinson's disease due to the fact that the bioavailability isgreatly improved.

The invention relates to a medicament based on rosmarinic acid and application thereof in treating Parkinson's disease. According to the formula of the medicament, the medicament comprises rosmarinic acid and sodium citrate with the molar concentration thereof being 1:104 to 1:1011. The medicament achieving the effect of neuroprotection in MES23.5 dopaminergic cells can obviously relieve the reduction in the survival rate of the MES23.5 cells caused by the induction of neurotoxin, i.e., 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenylpyridine cations, obviously relieve the reduction in the mitochondrial membrane potential of the cells caused by the induction of neurotoxin, i.e., 1-methyl-4-phenylpyridine cations and the generation of ROS (reactive oxygen species) substances and obviously improve the morphologic changes of nuclei caused by the induction of neurotoxin, i.e., 6-hydroxydopamine (6-OHDA) or 1-methyl-4-phenylpyridine cations, thereby achieving the effects of neuropretection, oxidation resistance and apoptosis resistance. The medicament of the invention having low toxicity and side effect has significant application prospect and actual value for the development into a novel anti-Parkinsonism natural medicament.

The invention provides a coumarin/pyridine hybrid derivative shown as the formula (I) or the formula (II) and pharmaceutically acceptable salt thereof. The coumarin/pyridine hybrid derivative and thepharmaceutically acceptable salt thereof can be applied in preparation of anti-Alzheimer and antiparkinsonian drugs or drugs for treating other diseases by inhibiting MAOs (monoamine oxidases) or chelating iron ions.

The invention relates to an application of a microsphere composition containing an antiparkinsonism drug to preparation of a medicine for preventing and treating parkinson diseases and complicating diseases of parkinson diseases. The microsphere composition containing the antiparkinsonism drug is selected from benserazide microspheres, L-dopa methyl ester microspheres, the L-dopa methyl ester microspheres and the benserazide microspheres, or L-dopa methyl ester and benserazide mixing drug microspheres. The invention also provides a microsphere combination medicament containing the antiparkinsonism drug. The invention explores novel medical application for the microsphere combination medicament containing the antiparkinsonism drug and develops a novel application field. The microsphere combination medicament containing the antiparkinsonism drug of the invention is safe and nontoxic, has strong pharmacological action and indicates good medicinal prospect.

The present application describes a composition comprising a neuroprotective effective amount of an antioxidant acetylsalicylic acid maltol ester (AME).

The present invention provides a chiral medicine intercalated hydrotalcite and its preparation method. The described chiral medicine is levodopa, said chiral medicine levodopa can be inlaid into the interlamination of hydrotalcite so as to obtain the invented product chiral medicine intercalated hydrotalcite with the effect of resisting Parkinson's disease. Said invention also provides its chemical structure formula.

The invention relates to new application of cytochalasin H in pharmacy, and particularly relates to the application of the cytochalasin H in preparation of Parkinson's disease resistant nerve-protective drugs. A series of in-vitro tests certificates that the cytochalasin H has significant protective effects on PC12 cellular damage induced by MPP +, and can be used to develop the Parkinson's disease resistant drugs.

The invention relates to a rasagiline/folic acid compound medicine combination and a purpose thereof, and belongs to the technical field of pharmacy. The medicine combination comprises the rasagiline with an officinal dose, the folic acid compounds with an officinal dose, and a carrier which can be accepted in pharmacy. The dose of the rasagiline is 0.5-2 mg, and the dose of the folic acid compounds is 0.2-1.6 mg. The medicine combination has the advantages that through synergistic effect of multiple target points, curative effect on the Parkinson's disease is improved, life quality of a patient is improved, through a homocysteine (Hcy) target point, cerebral apoplexy of the patient with the Parkinson's disease can be effectively prevented, occurring risk of the cerebral apoplexy can be effectively lowered, and in addition, the patient can conveniently take medicine.

The invention relates to a compound with anti-parkinsonism pharmacological activity, which is called baicalin, with a systematic name that: the anti-PD pharmacological activity of baicalin acting on two kinds of animals with parkinsonism disease shows that the baicalin can protect the nigrostriatal dopaminergic neurons of animals of a PD model. The research results comprise that: (1) researches are carried out to check whether the baicalin can protect mice with parkinsonism disease induced by 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine (MPTP); and (2) researches are carried out to check whether the baicalin can protect rats with parkinsonism disease induced by rotenone; and the results of the researches shows that the baicalin can protect the nigrostriatal dopaminergic neurons of animals of the PD model, can reduce the loss of the nigrostriatal dopaminergic neurons, promote the growth of dopaminergic neuron protuberances, prevent the reduction of striatum dopamine, decrease the percentage of praxeological change occurring on animals, reduce total praxeological credits and improve the praxeological symptom of PD rats. The pharmacological activity of the baicalin suggests that the baicalin has great application significance in stopping the development of Parkinsonism disease.

The invention relates to a pharmaceutical composition of levodopa/benserazide/folic acid compounds and a purpose thereof, and belongs to the technical field of pharmacy. The pharmaceutical composition comprises the levodopa with medical dose, the benserazide with the medical dose, the folic acid compounds with the medical dose and a carrier which can be accepted in the pharmacy. The dose of the levodopa is 100-300 mg, the dose of the benserazide is 30-70 mg, and the dose of the folic acid compounds is 0.2-1.6 mg. The pharmaceutical composition of the levodopa/the benserazide/the folic acid compounds and the purpose thereof have the advantages of enhancing the curative effect of Parkinson disease resistance and improving the quality of life of a patient through the synergistic effect of multiple target points; being capable of effectively preventing and lowering the occurring risk of cerebral apoplexy of a Parkinson disease patient through a homocysteine (Hcy) target point; and in addition, enabling the patient to take medicine conveniently.

The invention relates to a medicine combination of amantadine/folic acid compounds and a purpose thereof, and belongs to the technical field of pharmacy. The medicine combination comprises the amantadine with an officinal dose, the folic acid compounds with an officinal dose, and a carrier which can be accepted in pharmacy. The dose of the amantadine is 50-200 mg, and the dose of the folic acid compounds is 0.2-1.6 mg. The medicine combination has the advantages that through synergistic effect of multiple target points, curative effect on the Parkinson's disease is improved, life quality of a patient is improved, through a homocysteine (Hcy) target point, cerebral apoplexy of the patient with the Parkinson's disease can be effectively prevented, occurring risk of the cerebral apoplexy can be effectively lowered, and in addition, the patient can conveniently take medicine.

This invention is directed to the use of certain pharmaceutical compositions for treating and methods of treating Parkinson s disease. In particular, this invention is directed to pharmaceutical compositions for treating and methods of treating Parkinson s disease comprising the use of selective cyclooxygenase-2 inhibitors, such as rofecoxib, etoricoxib, celecoxib and valdecoxib, with and without concomitant use of one or more antiparkinson drugs.

The invention belongs to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine compound used for treating parkinson's disease and a preparation method and application thereof. The traditional Chinese medicine compound used for treating parkinson's disease is prepared from the following traditional Chinese medicines in parts by weight: 100-150 parts of radix polygonum multiflorum preparata, 80-120 parts of prunellae spica, 70-90 parts of vine of multiflower knotweed, 50-70 parts of radix salviae miltiorrhizae, 70-90 parts of semen ziziphi spinosae, 50-70 parts of radix scrophulariae, 70-90 parts of radix paeoniae alba, 30-50 parts of radix bupleuri, 50-70 parts of cortex albiziae and 20-40 parts of radix glycyrrhizae. The traditionalChinese medicine compound has an efficient effect of treating parkinson's disease, has low toxicity at the same time, and can be used for preparing an efficient low-toxic medicine for resisting parkinson's disease.